patent.fyi
Applications  /  US 2026/0355135
United States Patent Application Publication

US 2026/0355135 A1

Published
Nov 12, 2026
Filed
May 26, 2026
Earliest date on the face
Aug 26, 2024
Classification
A61K 31/19
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Direct inhibition of hexokinase

What ifWhat if 2-deoxy-D-glucose replaces dichloroacetate and limits glycolysis at its first phosphorylation step?
Claim language“(a) dichloroacetate”

Glucose transporters take up 2-deoxy-D-glucose, and hexokinase converts it to 2-deoxy-D-glucose-6-phosphate. The phosphorylated analog accumulates and inhibits hexokinase, reducing glucose entry into glycolysis.

1.1Restriction of lactate formation

What ifWhat if oxamate replaces dichloroacetate and limits the conversion of pyruvate to lactate?
Claim language“(a) dichloroacetate”

Oxamate competes with pyruvate at the substrate-binding site of lactate dehydrogenase. Blocking this reaction reduces lactate formation and slows the regeneration of NAD⁺ that supports glycolysis.

1.1Restriction of lactate export

What ifWhat if an inhibitor of monocarboxylate transporter 1 replaces dichloroacetate and restricts lactate export?
Claim language“(a) dichloroacetate”

The inhibitor blocks proton-coupled lactate transport through monocarboxylate transporter 1. In cells that rely on this transporter for lactate export, intracellular lactate accumulates and sustained glycolytic flux falls.

1.2Direct inhibition of farnesyltransferase

What ifWhat if a farnesyltransferase inhibitor that competes for the protein substrate site replaces perillyl alcohol?
Claim language“perillyl alcohol”

The inhibitor occupies the site that recognizes the carboxyl-terminal sequence of a protein substrate. This reduces transfer of the farnesyl group from farnesyl diphosphate to the substrate cysteine.

1.2Selective inhibition of geranylgeranyltransferase

What ifWhat if a selective inhibitor of geranylgeranyltransferase type I replaces perillyl alcohol?
Claim language“perillyl alcohol”

The inhibitor reduces transfer of a geranylgeranyl group from geranylgeranyl diphosphate to target proteins such as RhoA and Rac1. Reduced lipid attachment limits association of these proteins with cell membranes.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Metabolic profiling in cell culture

Dichloroacetate and perillyl alcohol are dispersed in a buffered carrier for use in a cell culture assay. Replicate wells receive the combined preparation, either active alone, or the carrier alone at the same final excipient concentration. Lactate concentration in the culture medium and oxygen consumption by the cells provide paired measurements of metabolic response.

Component substitution

Cyclodextrin carrier for perillyl alcohol

Hydroxypropyl beta cyclodextrin replaces a surfactant excipient as the solubilizing component. Perillyl alcohol is mixed into an aqueous cyclodextrin solution, where the cyclodextrin cavities associate with the hydrophobic portion of the alcohol. A separately prepared aqueous solution of sodium dichloroacetate is blended into the mixture to form a single liquid preparation.

Parameter or scale variation

Bench batches at three volumes

Three bench batches of the same dichloroacetate and perillyl alcohol formulation have final volumes of 25, 100, and 250 milliliters. Each batch uses the same target concentrations and is mixed in a straight-sided vessel with an impeller diameter equal to one-third of the vessel diameter. Samples from three liquid depths are assayed for both actives to assess uniformity at each scale.

Combination with existing systems

Flow testing with a barrier chip

A buffered formulation containing dichloroacetate and perillyl alcohol feeds the vascular channel of a two-channel microfluidic blood–brain barrier model. A porous membrane bearing cultured brain endothelial cells separates the vascular channel from a receiver channel supplied with fresh medium. Samples collected from both outlets at fixed intervals are analyzed for each active to calculate apparent permeability.

Continuous mixing with metered liquid feeds

One metering pump supplies aqueous dichloroacetate and a second supplies perillyl alcohol pre-dispersed in a liquid excipient. The two streams meet at a junction upstream of an in-line static mixer, and their flow rates set the final proportion of the actives. The outlet is sampled after the flows stabilize, and the concentrations of both actives are measured before collection begins.

Automated or data-driven variant

Automated formulation screening by liquid handling

A programmable liquid handler dispenses aqueous dichloroacetate stock and a perillyl alcohol concentrate into sealed glass wells. The dispense program varies the proportion of one active relative to the other and adds buffered vehicle to reach a fixed final volume and excipient concentration in every well. The software links the dispense volumes and plate positions to optical transmittance and chromatographic recovery measurements.

Specific version of a part

Dissolved sodium dichloroacetate

Sodium dichloroacetate dissolves in the aqueous phase and dissociates into sodium and dichloroacetate ions. The formulation expresses the active content as millimoles of dichloroacetate per milliliter.

Single enantiomer of perillyl alcohol

The composition contains the S enantiomer of perillyl alcohol. Gas chromatography with a chiral stationary phase separates the S and R enantiomers and measures their relative proportions.

Lecithin stabilized oil droplets

A medium-chain triglyceride phase holds perillyl alcohol in droplets dispersed through an aqueous phase containing dissolved sodium dichloroacetate. Lecithin coats the oil–water interface, and high-shear homogenization breaks the oil phase into smaller droplets.

Cyclodextrin inclusion complex

Hydroxypropyl beta-cyclodextrin forms an inclusion complex with perillyl alcohol in water. Dissolved sodium dichloroacetate supplies dichloroacetate ions in the same aqueous phase.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 8,609,724 B2
Published
Dec 17, 2013
Filed
Apr 11, 2006
Class
A61K 31/19
Document BUS 11,013,804 B2
Published
May 25, 2021
Filed
Apr 18, 2019
Class
A61K 45/06
Claim 1
Document A
Document B
1.1(a) dichloroacetate,
In one embodiment, the dichloroacetate is a salt of dichloroacetic acid.
A · US 8,609,724 B2 · ¶ 9
1.2(b) perillyl alcohol, and
A specific example of a monoterpene that may be used in the present invention is perillyl alcohol (commonly abbreviated as POH).
B · US 11,013,804 B2 · ¶ 54
1.3(c) at least one pharmaceutically acceptable carriers or excipients.
Accordingly, the present invention provides a pharmaceutical composition for treating a patient in need thereof, such as a human, comprising dichloroacetate or obvious chemical equivalent thereof of the invention and a pharmaceutically acceptable carrier, diluents or excipients.
A · US 8,609,724 B2 · ¶ 50
To prepare such pharmaceutical compositions, one or more of monoterpene (or sesquiterpene) derivatives may be mixed with a pharmaceutical acceptable carrier, adjuvant and/or excipient, according to conventional pharmaceutical compounding techniques.
B · US 11,013,804 B2 · ¶ 96

An empty cell means only that no passage was reproduced there.

Statements in these documents
As such there is a need for a cancer therapy that can overcome apoptosis resistance in cancer cells.
A · US 8,609,724 B2 · ¶ 3
In another embodiment, the inventors provide a method for inducing apoptosis in cancer but not normal cells.
A · US 8,609,724 B2 · ¶ 5
There is still a need to prepare perillyl alcohol derivatives including perillyl alcohol conjugated with other therapeutic agents, and use this material in the treatment of cancers such as malignant gliomas, as well as other brain disorders such as Parkinson's and Alzheimer's disease.
B · US 11,013,804 B2 · ¶ 6
The administration can also be through various routes including intranasal, oral, oral-tracheal for pulmonary delivery, and transdermal.
B · US 11,013,804 B2 · ¶ 6
Cite aspatent.fyi, US 2026/0355135 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355135/, SHA-256 82efd161e83c7c18486d5c8f44fa3aaa37529fb322ac31bb6994f5ec85ba8331
First published
Permanent addresshttps://patent.fyi/US20260355135/
Content fingerprint (SHA-256)82efd161e83c7c18486d5c8f44fa3aaa37529fb322ac31bb6994f5ec85ba8331
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi